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The intermediate-conductance Ca2+-activated K+ channel KCa3.1 (also called IKCa, IK1 and KCNN4) plays an 
essential role for the positive-feedback mechanism required for the enhancement of Ca2+ signaling in activated 
T-lymphocytes, and regulates the T cell activation, proliferation and differentiation. Recent reports have 
suggested that T-lymphocyte KCa3.1 K+ channel is an attractive target for the therapeutic strategies of 
inflammatory bowel disease (IBD). In addition, the potential KCa3.1 regulators also play critical roles in the T 
cell functions: phosphoinositide-3-kinase, class 2, beta polypeptide (PI3K-C2B), nucleoside diphosphate kinase 
B (NDPK-B), phosphohistidine phosphatase 1 (PHPT-1) and myotubularin related protein 6 (MTMR-6). We 
recently described that the up-regulation of KCa3.1 and NDPK-B might constitute an initiation step in CD4+ T-
lymphocyte proliferation in acute IBD and might be one of important mechanisms underlying the pathogenesis 
of IBD (Ohya et al., Am J Physiol Gastrointest Liver Physiol. 306:G873-G885). KCa3.1 K+ channel and its 
regulators may be potential therapeutic targets for inflammatory diseases such as IBD. 
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Introduction 
In the immune cells such as lymphocytes, mast cells and 
macrophages, Ca2+-activated K+ channel is characterized 
by an intermediate-conductance KCa3.1 channel [1]. In T-
lymphocytes, the activation of KCa3.1 channels by the 
intracellular Ca2+rise during T cell receptor (TCR)-evoked 
Ca2+ signaling hyperpolarizes the membrane potential, and 
thereby promotes Ca2+ influx via Ca2+-release activated 
Ca2+ (CRAC) channels composed of the complex of Orai 
and STIM families[2-4]. KCa3.1 channel plays an essential 
role for the positive-feedback mechanism required for the 
enhancement of Ca2+ signaling in activated T-lymphocyte. 
KCa3.1 expression is relatively low in quiescent human 
naive (TN), central memory (TCM), and effector memory 
(TEM) T cells. Upon T cell activation, KCa3.1 channel is up-
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regulated in TN and TCM cells, whereas voltage-gated K+ 
channel, KV1.3 instead of KCa3.1 is up-regulated in TEM 
cells [5, 6]. In addition, KCa3.1 currents are significant higher 
in helper T (Th1) cells compared with that in Th2 cells, 
corresponding to the larger Ca2+ signaling in Th1 cells [7]. 
Similar to the case with T cells, quiescent naive and early 
memory B cells express low levels of KCa3.1 channels, and 
effector cells derived from naive memory B cells express 
high levels of them[8]. KCa3.1 channel is a potential 
molecular target for pharmacological intervention in a 
variety of diseases, e.g. autoimmune diseases such as 
multiple sclerosis and rheumatoid arthritis, transplant 
rejection, sickle cell anemia, asthma, atherosclerosis, 
fibrosis, and traumatic brain injury [9-11]. 
Molecular determinants of KCa3.1 channel and its 
transcriptional factors 
KCa3.1/KCNN4 orthologs and their spliced isoforms 
have been molecularly identified from various species and 
tissues [12, 13]. Alternative splicing isoforms can function as 
the dominant-negative by incorporation into tetrameric K+ 
channel α subunits. In small-conductance KCa2.x channels, 
two different spliced isoforms, KCa2.3-1B and KCa2.3-1C 
lacking first transmembrane segment, have caused 
dominant-negative suppression of KCa2.x by trapping 
channel proteins intracellularly [14, 15]. Both KCa2.x and 
KCa3.1 have the dominant-inhibitory segment (DIS) in the 
C-terminus with the sequence similarity to tetramerization-
coiled-coiled domains, and DIS plays an essential role in 
KCa2.x and KCa3.1 tetrameric interactions [15]. We have 
recently identified the N-terminus-lacking spliced isoforms 
of KCa3.1 (KCa3.1-ΔN), from mammalian lymphoid tissues. 
KCa3.1-ΔN isoforms have shown dominant-negative effects 
on membrane trafficking and the channel activity of 
functional KCa3.1, KCa3.1-wt [13]. Additionally, up-
regulation and over-expression of KCa3.1-ΔN in mice 
thymocytes differentiated CD4+CD8+ double positive 
phenotype into CD4-CD8-double negative one, and 
suppressed concanavalinA-stimulated thymocyte growth 
by down-regulation of IL-2 expression[13].  
As transcriptional factors of KCa3.1, activator protein-1 
(AP-1) (Fos/Jun heterodimers) and repressor element-1 
silencing transcription factor (REST) have been identified 
[16, 17]. KCa3.1 gene expression is positively and negatively 
regulated by AP-1 and REST, respectively. Disease-
associated alternative splicing of KCa3.1 has not been 
identified yet, however, the increase in KCa3.1 channel 
activity by the down-regulation of KCa3.1-ΔN may have a 
critical role in the pathogenesis of inflammatory diseases. 
Potential therapeutic uses of KCa3.1 channel blockers 
In 1990’s, it has been reported that pharmacological 
blockade of KCa3.1 by clotrimazole (CLT) prevents sickle 
cell dehydration [18, 19]. However, the imidazole ring of CLT 
which is essential for the inhibition of hepatic cytochrome 
P450 enzyme activity has caused abnormal hepatic 
function [19]. To prevent cytochrome P450 inhibition by 
CLT, the imidazole ring has been chemically modified, and 
selective KCa3.1 blockers, TRAM-34 (1-[2-chlorophenyl] 
diphenylmethyl)-1H -pyrazole) (IC50=20 nM) [18] and ICA 
-17043(4-fluoro-α-phenylbenzaneacetamide) (Senicapoc) 
(Icagen Inc.) (IC50=11 nM) have been developed [20]. Also, 
novel chemical compounds as KCa3.1 blockers are 
developed by Brugnara et al.: 11-phenyl-dibenzazepine 
(IC50=90 nM) and diphenylindanone 12 (IC50=189 nM) 
(US patent No. US6992079, US7342038). 
Senicapoc has been evaluated in clinical trials for sickle 
cell anemia and asthma, however, phase II and III studies 
of Senicapoc for patients of these diseases have been 
recently terminated [21, 22]. Nevertheless, Senicapoc is 
recognized as a safe and well-tolerated drug because long-
term treatment with Senicapoc has shown no serious toxic 
and adverse effects in preclinical and clinical trials. Human 
lung mast cells (HLMC), which are implicated in the 
pathology of asthma, express high levels of KCa3.1 
channels, and pharmacological blockade of KCa3.1 
channels attenuates HLMC proliferation and migration [23]. 
Senicapoc has indicated the significant efficacy for the late 
asthmatic response (LAR) (www.pfizer.com). In addition 
to allergic asthma, KCa3.1 is a potential therapeutic target 
for inflammatory and autoimmune diseases. Genetic 
disruption and/or pharmacological blockade of KCa3.1 have 
indicated the significant efficacy for IgE-mediated 
anaphylaxis and DTH (delayed type hypersensitivity) [24, 25], 
and also developed less severe colitis in two different IBD 
model mice [26].In KCa3.1 knock-out mice, Th1 and Th2 
cells show smaller Ca2+ influx and cytokine production 
during TCR activation, whereas Th17 and regulatory T 
cells possess normal function. Moreover, agenome-wide 
association study has identified a certain KCa3.1 SNP 
(Single Nucleotide Polymorphism) (rs2306801) as a 
potential susceptibility factor in ileal Crohn's disease (CD) 
in the Australian and New Zealand populations [27].Clinical 
trials to evaluate the efficacy of Senicapoc and the other 
KCa3.1 blockers for inflammatory diseases will be 
conducted in near future. 
Functional regulators of KCa3.1 channel 
In CD4+ T-lymphocytes, KCa3.1 on histidine 358 
(His358) in the C-terminus is phosphorylated by NDPK-B, 
a positive KCa3.1 regulator, and dephosphorylated by 
PHPT-1, a negative KCa3.1 regulator [28, 29]. Genetic 
disruption of NDPK-B negatively regulates CD4+ T cells, 
and suppresses cytokine production in both T helper 1 (Th1) 
and Th2 cells [30]. In contrast, genetic disruption of PHPT-
1 positively regulates CD4+ T cells. Apart from these 
molecules, a certain phosphatidylinositol 3 kinase, PI3K-
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C2Bactivates KCa3.1 channel and positively regulates 
CD4+ T cells [31], whereas a certain PI3 phosphatase, 
MTMR6 inhibits KCa3.1 channel and negatively regulates 
CD4+ T cells [32]. Recently, it has been reported that 
tripartite motif containing protein 27 (TRIM27), a member 
of Really Interesting New Gene (RING) E3 ubiquitin 
ligases, functions as a negative 
regulator of PI3K-C2B [33]. By inhibiting PI3K-C2B, 
TRIM27 suppresses KCa3.1 channel activity, and thereby 
decreases TCR-stimulated Ca2+ influx, proliferation, and 
cytokine production in T-lymphocytes [33]. Taken together, 
positive regulators (NDPK-B and PI3K-C2B) and negative 
regulators (PHPT-1, MTMR6 and TRIM27) of KCa3.1 K+ 
channel may provide new strategies for the treatment of 
inflammatory, autoimmune and allergic diseases. 
Localization of KCa3.1 channel and its interacting 
molecules in immunological synapse 
The immunological synapse (IS) is a highly organized 
structure triggered by sustained TCR engagement on the 
surface of an antigen-presenting cell (APC), and is 
characterized by an extensive reorganization of signaling 
proteins to the T cell-APC contact zone. The IS formation 
plays an essential role in both the initiation and the 
maintenance of immune responses [34]. Similar to ion 
channels contributing to T-lymphocyte Ca2+ signaling, 
such as CRAC and KV1.3 channels, KCa3.1 channels are 
recruited to the IS upon antigen stimulation, and become 
part of the signaling complex that facilitates T cell 
proliferation and cytokine production[35]. However, the 
distribution of KCa3.1 channels to the IS is not prevented by 
pharmacological blockade of KCa3.1 channel activity, and 
the increase in Ca2+ influx mediated by KCa3.1 channel 
activation does not contribute to the initiation and the 
maintenance of IS formation. 
Functional regulators of KCa3.1 channel, NDPK-B, 
PHPT-1, PI3K-C2B, and MTMR6 are recruited to the IS, 
and spatial arrangement in the IS of them is critical to 
KCa3.1 channel regulation. NDPK-B and PHPT-1, which 
are coupled in the C-terminus of KCa3.1 channel, form the 
clustering at the IS together with KCa3.1 channel [28, 29] (Fig. 
1). At the IS, NDPK-B interacts with the integrin 
cytoplasmic domain-associated protein A (ICAP1A), 
linking KCa3.1 to β-integrin [36]. Moreover, PI3K-C2B 
colocalizes with Zap70 (ζ-Chain-Associated Protein 
Kinase 80) and p56lck in peripheral micro clusters, and is 
recruited to the IS during antigen stimulation [31]. 
Recruitment of NDPK-B and PI3K-C2B with KCa3.1 to the 
peripheral zone, p-SMAC (peripheral supramolecular 
activating complex) in the IS is critical for the KCa3.1 
channel activation. In contrast, localization of MTMR6 and 
PHPT-1 to the central supramolecular activating complex 
(c-SMAC) segregates KCa3.1 from p-SMAC, and could 
Figure 1. Signal molecules involving in KCa3.1 K+ channel distribution and Ca2+ signal in the immunological synapse. 
ICAP: integrin cytoplasmic domain-associated protein. p56lck: lymphocyte-specific tyrosine protein kinase. ZAP: zeta-chain-
associated protein kinase. NDPK: nucleoside diphosphate kinase. PI3K: class II phosphatidylinositol 3 kinase. PHPT: 
phosphohistidine phosphatase. MTMR: myotubularin-related protein. TRIM: tripartite motif. CAM: calmodulin. CRAC: Ca2+ 
release-activated Ca2+ channel. p-SMAC: peripheral-supramolecular adhesion complex. c-SMAC: central-SMAC.  
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provide one possible mechanism underlying the negative 
regulation of KCa3.1 channel activity [31]. Further 
comprehensive study on the molecules forming Ca2+ signal 
complex sorted to the p-SMAC of the IS may enable the 
novel drug design for inflammatory, autoimmune and 
allergic diseases. 
Ubiquitin-mediated KCa3.1 channel protein degradation 
A balance between the translation and the degradation of 
ion channels is of importance to regulate its activity. Small-
conductance KCa2.3 channel protein is rapidly endocytosed 
and recycled back to the plasma membrane. Recycling of 
KCa2.3 channel protein is dependent upon REM1 and 
Rab35 [37]. In contrast, KCa3.1 channel protein is rapidly 
(60-90 min after membrane trafficking) endocytosed, 
however, does not enter the recycling pathway. Subsequent 
to endocytosis, KCa3.1 channel proteinis targeted to the 
lysosomes for degradation in Rab7- and ESCRT 
(Endosomal Sorting Complex Required for Transport)-
dependent pathway [38]. Therefore, the inhibition of 
ubiquitin-activating enzymes results in reduced 
ubiquitylation and internalization of KCa3.1 channel 
proteins, and accordingly the ubiquitylase inhibitors 
attenuate KCa3.1 degradation. Deubiquitylase USP-8 
(Ubiquitin Specific Protease 8) interacts with KCa3.1 
channel protein, and siRNA-mediated USP-8 knock-out 
enhances the accumulation of ubquitylated KCa3.1 channel 
proteins [39]. Interestingly, a high-throughput screening 
method has been developed to identify small-molecule 
modulators of KCa3.1 channel endocytosis using 
fluorescence-tagged KCa3.1. Using this novel method, the 
ubiquitin-activating enzyme, E1 inhibitor, UBEI-41 has 
been identified as an inhibitor of KCa3.1 channel 
endocytosis [40]. The inhibition of deubiquitylases and the 
activation of ubiquitin-activating enzymes for KCa3.1 
channels by pharmacological and/or genetic methods may 
possibly be novel strategies for drug development of 
inflammatory, autoimmune and allergic diseases. 
Future direction 
We recently showed that KCa3.1 inhibitors may be a 
therapeutic potential for DTH [41] and IBD [42]. In both 
auricular lymph node CD4+ T-lymphocytes of DTH model 
and mesenteric lymph node CD4+ T-lymphocytes in IBD 
model, an increase in KCa3.1 activity concomitant with an 
up-regulation of KCa3.1 was observed. Pharmacological 
blockade of KCa3.1 elicited the significant decrease in 
disease severity. It is of important that the pharmacological 
blockade of KCa3.1 is associated with the down-regulation 
of KCa3.1 in lymph node CD4+ T-lymphocytes in both Th1-
mediated disease models. These findings may provide 
novel information about radical treatments for 
inflammatory, autoimmune and allergic diseases. In 
addition, we suggest that KCa3.1 regulators such as NDPK-
B may be potential therapeutic targets to decrease the risk 
of the disease development. 
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